Dr. Zhenyu He: Precision Breast Radiation Oncology, Target Optimization & Radio-Immunotherapy at Sun Yat-sen University Cancer Center

Professional Profile

Dr. Zhenyu He is a renowned clinical radiation oncologist, Chief Physician, Doctoral Supervisor, and Deputy Director of the Department of Radiation Oncology at Sun Yat-sen University Cancer Center (SYSUCC). With decades of academic leadership at one of Asia’s preeminent cancer centers, Dr. He has spearheaded the clinical standardization and technological evolution of breast cancer radiotherapy in China.

Dr. He’s clinical philosophy integrates extreme anatomical precision with biological optimization. By harmonizing modern image-guided volumetric arc therapy with cutting-edge organ-motion management and systemic immunotherapies, his team achieves exceptionally high local control rates while minimizing cardiopulmonary toxicity, setting a recognized benchmark for both early-stage and complex locally advanced breast cancer care.

Key Clinical Specializations

• Postoperative Adjuvant Radiotherapy: Designing highly conformal intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) plans for breast-conserving surgery (with simultaneous integrated boost / SIB) and post-mastectomy radiation therapy (PMRT) encompassing internal mammary and supraclavicular lymph node chains.
• Cardiopulmonary Protection & DIBH Technique: Pioneering the routine clinical application of Deep Inspiration Breath Hold (DIBH) and surface-guided radiation therapy (SGRT) for left-sided breast cancer, physically displacing the cardiac silhouette away from the chest wall radiation field to safeguard long-term cardiovascular health.
• Multidisciplinary Care for Locoregionally Recurrent Breast Cancer: Formulating individualized salvage chemoradiotherapy and precision re-irradiation protocols for patients experiencing chest wall or nodal recurrence following prior therapy.
• Radio-Immunotherapy Combinations: Investigating synergistic immunogenic cell death mechanisms induced by hypofractionated radiation in combination with immune checkpoint inhibitors for triple-negative and treatment-refractory breast cancers.

Academic Leadership & Landmark Research (2024–2025)

Dr. Zhenyu He is an influential contributor to global radiation oncology literature, with key research featured in leading specialized journals such as Radiotherapy and Oncology (the Green Journal):

• Landmark Studies in Radiotherapy and Oncology: Authoring pivotal multi-center investigations optimizing target volume delineation (CTV/PTV) and evaluating normal tissue complication probability (NTCP) models to personalize radiation dosing in locally advanced breast cancer.
• Radio-Immunotherapy Clinical Trials: Serving as principal investigator on clinical protocols assessing the immunological priming effects and safety profile of thoracic radiotherapy combined with anti-PD-1/PD-L1 antibodies in high-risk breast oncology cohorts.
• National Consensus Guidelines: Leading and contributing to national clinical practice guidelines on target contouring, cardiopulmonary dose constraints, and hypofractionated whole-breast irradiation protocols.

International Patient Coordination & Fast-Track Access

China Medical Concierge – Shanghai (CMCS) provides dedicated health management and medical concierge services connecting patients across Greater China and overseas with top-tier oncologists. For patients seeking medical evaluation and advanced radiation planning with Dr. Zhenyu He at SYSUCC, CMCS offers comprehensive support:

• Remote multidisciplinary review of previous radiation charts, CT simulation scans, and pathology reports;
• Expedited outpatient appointments and priority simulation scheduling at the SYSUCC Radiation Oncology Center;
• Second opinions on target volume contours, cardiopulmonary dose-volume constraints, and radio-immunotherapy trial eligibility;
• Full-course medical translation, bilingual patient accompaniment, and longitudinal radiation toxicity monitoring.